LG AI Research is pursuing the discovery of oral peptide drugs using artificial intelligence. The initiative aims to design peptides that can be taken orally, overcoming a key challenge in peptide therapeutics. The project leverages LG's proprietary AI models for molecular design and optimization.
LG AI Research has announced a new initiative focused on using artificial intelligence to discover oral peptide drugs. The project aims to design peptides that can be administered orally, addressing a major limitation of current peptide therapeutics which typically require injection.
The company is leveraging its proprietary AI models to generate and improve peptide sequences with improved stability and bioavailability /tools/peptide-bioavailability . This approach could significantly accelerate the development of oral peptide drugs.
Peptides are generally poor candidates for oral delivery due to degradation in the gastrointestinal tract and poor absorption. LG AI Research's AI system is designed to predict molecular properties that enable oral bioavailability.
The AI models analyze vast chemical spaces to identify peptide candidates that can survive stomach acid and enzymes while being absorbed into the bloodstream. This computational approach reduces the need for extensive laboratory screening.
If successful, AI-designed oral peptides could transform treatment options for various diseases. Patients would benefit from more convenient dosing /tools/peptide-dosage-planner compared to injectable biologics.
LG AI Research's work represents a convergence of artificial intelligence and pharmaceutical science. The company has not disclosed specific therapeutic targets or timelines for clinical development.
The oral peptide discovery program is part of LG AI Research's broader strategy to apply AI to life sciences. The organization has previously developed AI models for protein structure prediction and drug discovery.
By focusing on oral peptides, LG AI Research is targeting a high-value area of drug development. The global peptide therapeutics market continues to grow, with oral formulations representing a significant unmet need.
Related reading: LG AI Research and D&D Pharmatech Partner on Oral Peptide Drug Discovery, Semaglutide Conference Presentation Highlights at ADA 86th Scientific Sessions, MHC Class I vs II Peptide Binding: T Cell Presentation Explained, Peptide Mass Calculator: Molecular Mass and Key Properties for Research.